Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Actuate Therapeutics, Inc. ( (ACTU) ) has shared an update.
On June 25, 2025, Actuate Therapeutics, Inc. entered into a securities purchase agreement for a private placement with institutional and accredited investors, aiming to raise approximately $4.7 million. The funds are intended for working capital and general corporate purposes, with the private placement expected to close by June 30, 2025. Additionally, the company has committed to a registration rights agreement to facilitate the resale of shares and warrants, with a filing deadline set for August 9, 2025. This strategic move is anticipated to bolster Actuate’s financial position and support its ongoing drug development efforts, particularly for elraglusib, which is awaiting potential FDA breakthrough therapy designation.
The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of innovative therapeutics. The company is primarily engaged in the research and development of drugs, with a significant focus on elraglusib, a potential treatment that is currently undergoing clinical trials.
Average Trading Volume: 67,561
Technical Sentiment Signal: Strong Sell
For an in-depth examination of ACTU stock, go to TipRanks’ Overview page.